Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rotrosen

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
Contemporary Clinical Trials|January 22, 2025
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorderKathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, et al.
Addiction Science & Clinical Practice|April 10, 2018
Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staffJennifer McNeely, Pritika C Kumar, Traci Rieckmann, et al.
Addiction (Abingdon, England)|March 19, 2025
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational dataSara Lodi, Shapei Yan, Benjamin Bovell-Ammon, et al.
JAMA Psychiatry|August 24, 2022
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical TrialMichael P Bogenschutz, Stephen Ross, Snehal Bhatt, et al.
The American Journal on Addictions|August 15, 2018
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trialAimee N C Campbell, Celestina Barbosa-Leiker, Mary Hatch-Maillette, et al.
The American Journal on Addictions|August 16, 2023
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorderMargaret Paschen-Wolff, Shelly F Greenfield, R Kathryn McHugh, et al.
The American Journal on Addictions|May 22, 2020
Substance Use and Mental Health in Emerging Adult Vs Older Adult Men and Women With Opioid Use DisorderCelestina Barbosa-Leiker, Aimee N C Campbell, Martina Pavlicova, et al.
Journal of Substance Abuse Treatment|October 24, 2007
Smoking cessation treatment in community-based substance abuse rehabilitation programsMalcolm S Reid, Bryan Fallon, Susan Sonne, et al.
Drug and Alcohol Dependence|May 6, 2014
Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trialThomas R Kosten, Coreen B Domingo, Daryl Shorter, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
Contemporary Clinical Trials|January 22, 2025
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorderKathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, et al.
Addiction Science & Clinical Practice|April 10, 2018
Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staffJennifer McNeely, Pritika C Kumar, Traci Rieckmann, et al.
Addiction (Abingdon, England)|March 19, 2025
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational dataSara Lodi, Shapei Yan, Benjamin Bovell-Ammon, et al.
JAMA Psychiatry|August 24, 2022
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical TrialMichael P Bogenschutz, Stephen Ross, Snehal Bhatt, et al.
The American Journal on Addictions|August 15, 2018
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trialAimee N C Campbell, Celestina Barbosa-Leiker, Mary Hatch-Maillette, et al.
The American Journal on Addictions|August 16, 2023
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorderMargaret Paschen-Wolff, Shelly F Greenfield, R Kathryn McHugh, et al.
The American Journal on Addictions|May 22, 2020
Substance Use and Mental Health in Emerging Adult Vs Older Adult Men and Women With Opioid Use DisorderCelestina Barbosa-Leiker, Aimee N C Campbell, Martina Pavlicova, et al.
Journal of Substance Abuse Treatment|October 24, 2007
Smoking cessation treatment in community-based substance abuse rehabilitation programsMalcolm S Reid, Bryan Fallon, Susan Sonne, et al.
Drug and Alcohol Dependence|May 6, 2014
Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trialThomas R Kosten, Coreen B Domingo, Daryl Shorter, et al.
Pageof 16